What is ACUT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACUT?

P/E (TTM) is n/a and 52-week range is $0.12 to $1.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACUT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACUT?

The company profile lists net income (TTM) near $-2M, EPS (TTM) near $-0.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Accustem Sciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 16.1M shares outstanding, ISIN US00444A1016 when available from company profile and filing metadata.

Accustem Sciences Inc

$ACUT

Health Care · Biotechnology

IR Run Scenarios

$0.15

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

AccuStem Sciences, Inc. is a clinical stage diagnostics company, which engages in medical practice activities. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2022-03-01. The company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The company focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.

Employees

Website

accustem.com/

IPO

2022-03-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)